Note: All changes are versus the prior-year period unless otherwise stated
"Regeneron had outstanding performance in the second quarter during which we delivered to the US government the entire order for our COVID-19 antibody cocktail and recognised record global sales from our Eylea and Dupixent franchises," remarked CEO Leonard Schleifer. The company noted that when excluding sales of its REGEN-COV antibody cocktail, quarterly revenues still increased 22%.
Regeneron Pharmaceuticals noted that it has fulfilled its second agreement with the US government and delivered 1.25 million doses of REGEN-COV. Other than $34 million of expected REGEN-COV product sales in the third quarter related to this agreement, Regeneron said it does not expect any revenue from the COVID-19 antibody cocktail in the US in the third quarter.
Meanwhile, US sales of REGEN-COV in the fourth quarter "will be dependent upon acceleration of COVID-19 cases and related drug utilisation," it added. In May, the company said it expected sustained demand for the therapy even in the face of mass vaccine rollouts in the US. The FDA recently updated the emergency-use authorisation for REGEN-COV with a lower dose, subcutaneous administration and post-exposure prophylaxis.
To read more Top Story articles, click here.